REPL

REPL Profile

  • Sector: Health Technology
  • Industry: Biotechnology
  • Employees: 122

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Services We Offer

Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!

Machine Learning

Custom Scraper

Automation

Consulting